El-Mahdy, M., Mourad, F., Afify, W. (2001). Serum levels of soluble CD95 in patients with systemic lupus erythematosus. The Egyptian Journal of Hospital Medicine, 3(1), 36-46. doi: 10.21608/ejhm.2001.18892
Magda I. M. El-Mahdy; Fatma A. Mourad; Wafaa Afify. "Serum levels of soluble CD95 in patients with systemic lupus erythematosus". The Egyptian Journal of Hospital Medicine, 3, 1, 2001, 36-46. doi: 10.21608/ejhm.2001.18892
El-Mahdy, M., Mourad, F., Afify, W. (2001). 'Serum levels of soluble CD95 in patients with systemic lupus erythematosus', The Egyptian Journal of Hospital Medicine, 3(1), pp. 36-46. doi: 10.21608/ejhm.2001.18892
El-Mahdy, M., Mourad, F., Afify, W. Serum levels of soluble CD95 in patients with systemic lupus erythematosus. The Egyptian Journal of Hospital Medicine, 2001; 3(1): 36-46. doi: 10.21608/ejhm.2001.18892
Serum levels of soluble CD95 in patients with systemic lupus erythematosus
1Clinical Pathology Departments Faculty of Medicine for Girls, Al Azhar University
2Internal Medicine Departments Faculty of Medicine for Girls, Al Azhar University
3Dermatology Departments Faculty of Medicine for Girls, Al Azhar University
Abstract
The present study was carried out on 30 patients with systemic lupus erythematosus (SLE) and ten apparently healthy individuals as a control group.Systemic lupus erythematosus activity index (SLEDAI) was applied to all patients. Anti-double stranded DNA antibodies (Anti-dsDNA Abs.) , interleukin-18 (IL-18) and soluble CD95 (Apo-1/Fas) were determined in the sera of all studied subjects. The mean ±SD SLEDAI in all patients was 15.25± 6.76 . The anti-dsDNA antibodies was positive in all studied patients (mean ± SD 264.36 ± 114.85 IU/ml). Serum IL-18 showed significant elevation in SLE patients as compared to the control group (Mean ±SD 246.13± 114.32I U/ml vs. 45.5 ± 7.32 IU/ml ; p < 0.001). Serum Soluble CD95 (sCD95)showed significant increase in all SLE patients as compared to the control group (Mean±SD 648±116.96 pg/ml vs. 270±50.24 pg/ml ;p < 0.001). Serum sCD95 also showed significant rise in SLE patients with moderate activity as compared to those with mild activity (Mean ± SD 629.16± 72.54 pg/ml vs. 535 ±35.97 pg/ml; p<0.05). The serum level of sCD95 in SLE cases with severe activity showed significant increase when compared to those with moderate activity ( Mean±SD 797.5 ± 41.66 pg/ml vs. 629.16 ± 72.54 pg/ml ; p <0.001). Anti-dsDNA antibodies showed significant positive correlation with SLEDAI (r=0.772;p<0.01). IL-18 also showed a significant positive correlation with the SLEDAI (r=0.670 ;p<0.01). Soluble CD95 showed significant positive correlation with SLDAI (r=0.865 ; p<0.01), with anti-dsDNA antibodies (r=0.775 ;p<0.01) and with IL-18 (r =0.722 ; p<0.01). From these results it was concluded that serum sCD95 is increased in patients with systemic lupus erythematosus and it is correlated with anti-dsDNA antibodies , with IL- 18 and with the disease activity, so it can be useful marker of disease activity for proper management and follow up of SLE patients.